Galderma presents Nemluvio data as Galderma stock reaches CHF 39.7 billion value

Published on 10/13/2026 at 09:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Galderma stock costs EUR 182.35 on October 13, 2026. Sales rose 24.60 percent to USD 3.10 billion in the first half of 2026.

Key points in brief

Galderma presented three-year Nemluvio data on October 8, 2026, extending the drug's clinical evidence.
First-half 2026 net sales rose 24.60 percent to USD 3.10 billion, while full-year growth guidance stands at 19.00-21.00 percent.
Galderma stock was at EUR 182.35 at Lang & Schwarz on October 13, 2026, and the company had a CHF 39.7 billion market capitalization.
Galderma is listed on SIX and is a member of the SMI.

Galderma, CH1335392721, Illustration mit AI erstellt.

Galderma stock was valued at CHF 39.7 billion while the company presented three-year Nemluvio data on October 8, 2026. The latest Lang & Schwarz indication was EUR 182.35 on October 13, 2026 at 9:49 a.m. CEST.

Nemluvio data extend the story

Finanznachrichten reported on October 8, 2026 that Galderma presented new Nemluvio data from the ARCADIA long-term extension study. The release described sustained skin lesion and itch responses for up to three years in patients with atopic dermatitis and long-term results in prurigo nodularis.

The clinical update gives the dermatology group a concrete product milestone alongside its financial growth. Galderma's first-half 2026 net sales rose 24.60 percent at constant currency, making operating execution and the Nemluvio launch the central figures for the current investment case.

Three dated milestones carry figures

On April 22, 2026, Galderma said shareholders approved a gross dividend of CHF 0.35 per dividend-bearing share at the annual meeting.

On September 21, 2026, Galderma reported that first-half 2026 net sales increased 24.60 percent at constant currency. The company also lifted its full-year 2026 net sales growth guidance to 19.00-21.00 percent from 17.00-20.00 percent and reaffirmed Core EBITDA margin guidance of approximately 26.00 percent.

On October 8, 2026, the Nemluvio update added a clinical-data milestone to that chronology. The combination of a 24.60 percent first-half sales increase and a 19.00-21.00 percent full-year growth range leaves execution, rather than a lack of strategic ambition, as the key measurable issue.

What dates matter next?

MarketScreener lists October 22, 2026 as the date for Galderma's third-quarter sales and revenue release. That date is the next scheduled company event visible in the cited calendar.

Stock valuation and trading view

Galderma Group AG is listed on SIX under the ticker GALD and belongs to the SMI. The finance quote for October 13, 2026 showed a CHF 39.7 billion market capitalization and a 52-week range of CHF 134.70 to CHF 188.25.

The current euro indication sits below the Swiss 52-week high in a different currency, so the two values are not netted against each other. For investors, the cleaner comparison remains the operating record: first-half sales growth of 24.60 percent, a raised 19.00-21.00 percent full-year range and a 26.00 percent Core EBITDA margin guide.

Galderma stock stays tied to execution

At Lang & Schwarz, Galderma stock was trading at EUR 182.35 on October 13, 2026 at 9:49 a.m. CEST. The clinical data, the first-half sales figure and the October 22 reporting date give the stock a defined set of company-specific reference points.

The further course of trading is shown by the continuously updated real-time quote of Galderma stock.